Last reviewed 2026-04-22 · How we verify

Rivaroxaban and aspirin 80

This combination uses rivaroxaban to inhibit Factor Xa in the coagulation cascade while aspirin inhibits platelet aggregation, providing dual anticoagulant and antiplatelet effects.

This combination uses rivaroxaban to inhibit Factor Xa in the coagulation cascade while aspirin inhibits platelet aggregation, providing dual anticoagulant and antiplatelet effects. Used for Thromboprophylaxis in acute coronary syndrome or cardiovascular disease.

At a glance

Mechanism of action

Rivaroxaban is a direct Factor Xa inhibitor that blocks a key step in the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation. Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet aggregation. Together, they provide complementary anticoagulant and antiplatelet mechanisms for thromboprophylaxis.

Approved indications

• Thromboprophylaxis in acute coronary syndrome or cardiovascular disease

Common side effects

• Bleeding
• Gastrointestinal bleeding
• Dyspepsia
• Bruising

Key clinical trials

• Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
• PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
• Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
• Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS) (PHASE2, PHASE3)
• Rivaroxaban Post Coronary Bypass Surgery (PHASE4)
• Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.